Guest column : What Pegasys says about IPR in India

On November 2, the Indian Intellectual Property Appellate Board (IPAB) revoked Hoffmann-La Roche’s patent on the hepatitis C drug Pegasys.  In particular, the IPAB found that Roche failed to demonstrate Pegasys is more efficacious than an earlier version of the drug.  Read the ruling here. The ruling brings three critical issues to the fore. The …

Advertisement

Roche’s Emcure deal – thumbs up for market economics?

My colleague Vikas Dandekar of Pharmasianews reports on a potentially pathbreaking event. Swiss drug maker Roche has struck a manufacturing deal with Pune's Emcure to produce some portion of its blockbuster biologic Herceptin for breast cancer and Pegasys for hepatitis B and C in India for India. Of course, it doesn't look as if Emcure …